Business Wire

Haga Hospital in the Netherlands to Install State-of-the-Art MRI Ablation Center

Share

Imricor announced today that they have signed a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit an MRI ablation center for treating cardiac arrhythmias.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005217/en/

F.L.T.R. sitting: Karel Ronday, Director of Medical Affairs Haga Hospital and Steve Wedan, CEO of Im ...

F.L.T.R. sitting: Karel Ronday, Director of Medical Affairs Haga Hospital and Steve Wedan, CEO of Imricor Medical Systems F.L.T.R. standing: Cardiologist Hemanth Ramanna; Cardiologist Ivo van der Bilt; Cardiologist Vincent van Driel; Director of Sales Imricor Greg Englehardt; Not pictured: Manager Haga Heart Center Edith Bense (Photo: Business Wire)

This advanced MRI ablation center will contain a 1.5T MRI scanner and Imricor’s Advantage-MRTM EP Recorder/Stimulator System. This installation will establish the Haga Hospital and Heart Center as a world leader in the field of interventional cardiac magnetic resonance (iCMR) and place them among the first heart centers in the world to clinically adopt MRI-guided cardiac ablations.

“At the Haga MRI ablation center, we will be focusing on treating patients with arrhythmias with a more focused individualized ablation treatment plan. Performing the ablation in the MRI will give us the ability to adjust to each individual patient and allow us to make and assess the ablation lesion,” said Dr. Vincent van Driel, Director of Electrophysiology at the Haga Heart Center. “This project has been the most collaborative effort between 3 entities (hospital, physicians and industry) that I have ever been a part of. The willingness to work together is one key reason why this is becoming possible here at Haga Hospital.”

“Establishing the MRI ablation center at Haga Hospital marks an important milestone for the field of iCMR and, of course, for Imricor,” said Steve Wedan, Imricor’s CEO. “Haga is the first non-university hospital to make the move toward MRI guided ablations, and we feel that delivers a strong statement in support of this exciting field. We continue to be humbled by the extraordinary caliber of the medical leaders we get to work with, and we are so proud to be partnered with everyone at Haga Hospital.”

Cardiac procedures guided by MRI provide physicians with sophisticated soft tissue visualization that allows them to individualize treatment strategies for each patient’s unique cardiac structure and substrate as well as assess changes in tissue characteristics immediately post ablation. These benefits have the potential to improve patient outcomes and provide safer, more cost-effective treatment – all in an environment that is free of radiation for both the patient and physician.

About Imricor

Imricor Medical Systems is a privately held company committed to unlocking the potential of interventional cardiac magnetic resonance (iCMR) by delivering MR-compatible systems and devices that allow physicians to perform cardiac ablations under real-time MRI-guidance.

About Haga Hospital

The Haga Teaching Hospital is a large top clinical hospital in The Hague region. The Hospital is specialized in Heart care and surgery with one of the best results in terms of health outcomes in the country. The hospital also offers pediatrics in the Juliana Child Hospital, which is part of the hospital. It is one of the largest and most modern Accident and Emergency Departments in the region for adults and children.

CAUTION: The Advantage-MRTM EP Recorder/Stimulator System has received CE mark approval; it has not yet been approved for use in the United States. The Vision-MRTM Ablation Catheter has been approved as an investigational device for clinical studies in Europe. All other Imricor devices are not yet approved for use in humans.

Contact information

Steve Wedan - Imricor
+1 952.818.8417; info@imricor.com
www.imricor.com

Elly van Schaik
+31 06-22748796; E.vSchaik@hagaziekenhuis.nl
https://www.hagaziekenhuis.nl

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CESTPress release

SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti

Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CESTPress release

In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs

Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CESTPress release

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp

Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family11.10.2019 02:00:00 CESTPress release

Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/ Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation) This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability. Development Background Advanced proces

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis10.10.2019 22:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005875/en/ “We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “These data suggest that filgotinib if approved, may play an important role in helping people living with rheumatoid arthritis achieve sustained, clinically meaningful responses.” “The

Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 201910.10.2019 20:05:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, October 26, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the con